Top

Published in:

01-08-2006

Cyclooxygenase-2 Expression Correlates With Membrane-Type-1 Matrix Metalloproteinase Expression in Colorectal Cancer Tissue

Authors: Hongfei Guo, M.D., Atsushi Tatsuguchi, M.D., Seiichi Shinji, M.D., Shunji Fujimori, M.D., Shu Tanaka, M.D., Katya Gudis, M.S., Yuichi Sugisaki, M.D., Kiyonori Furukawa, M.D., Takashi Tajiri, M.D., Yuh Fukuda, M.D., Teruyuki Kishida, M.D., Choitsu Sakamoto, M.D.

Published in: Diseases of the Colon & Rectum | Issue 8/2006

Purpose

Elevated expression of cyclooxygenase-2 has been found in colorectal cancer. One of the mechanisms through which cyclooxygenase-2 affects tumorigenesis is through its overexpression, which leads to increased invasiveness of cancer cells. A crucial step in this pathway is thought to be the induction of membrane-type-1 matrix metalloproteinase, which activates matrix metalloproteinase-2. However, to date there have been few clinicopathologic studies concerning cyclooxygenase-2-mediated invasiveness in human colorectal cancer tissues.

Methods

We performed immunohistochemical analysis of the respective antigens on colorectal cancer specimens obtained by surgical resections from 96 patients with colorectal cancer.

Results

Cyclooxygenase-2 and membrane-type-1 matrix metalloproteinase expression was positive exclusively in cancer cells in 88 cases (92 percent) and 23 cases (24 percent), respectively. All 23 cases expressing membrane-type-1 matrix metalloproteinase also expressed cyclooxygenase-2. Matrix metalloproteinase-2 expression was positive in cancer cells in 20 cases (21 percent) and stromal cells in 52 cases (54 percent). Expression of matrix metalloproteinase-2 in cancer cells correlated with lymphatic invasion and local recurrence. Statistically, a significant correlation was found between cyclooxygenase-2 and membrane-type-1 matrix metalloproteinase expression, and membrane-type-1 matrix metalloproteinase and matrix metalloproteinase-2 expression in cancer cells. There was no association between cyclooxygenase-2 expression and matrix metalloproteinase-2 expression. However, immunostaining of serial sections revealed that in the majority of cases examined, nearly 100 percent of cancer cells expressing matrix metalloproteinase-2 also coexpressed cyclooxygenase-2.

Conclusions

This study indicates strong association between both cyclooxygenase-2 and membrane-type-1 matrix metalloproteinase expression, and membrane-type-1 matrix metalloproteinase and matrix metalloproteinase-2 in colorectal cancer. These results support our thesis of a direct correlation between cyclooxygenase-2 and membrane-type-1 matrix metalloproteinase expression—with consequent association between cyclooxygenase-2 and matrix metalloproteinase-2 activation, and tumor invasiveness andrecurrence in certain cases of colorectal cancer.

Pollard, M, Luckert, PH 1980Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumorsCancer Treat Rep6413231327PubMed

Reddy, BS, Maruyama, H, Kelloff, G 1987Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor developmentCancer Res4753405346PubMed

Kune, GA, Kune, S, Watson, LF 1988Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer StudyCancer Res4843994404PubMed

Thun, MJ, Namboodiri, MM, Heath, CW,Jr 1991Aspirin use and reduced risk of fatal colon cancerN Engl J Med32515931596PubMedCrossRef

Thun, MJ, Namboodiri, MM, Calle, EE, Flanders, WD, Heath, CW,Jr 1993Aspirin use and risk of fatal cancerCancer Res5313221327PubMed

Giovannucci, E, Egan, KM, Hunter, DJ, et al. 1995Aspirin and the risk of colorectal cancer in womenN Engl J Med333609614PubMedCrossRef

Smalley, W, Ray, WA, Daugherty, J, Griffin, MR 1999Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based studyArch Intern Med159161166PubMedCrossRef

Langman, MJ, Cheng, KK, Gilman, EA, Lancashire, RJ 2000Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research databaseBMJ32016421646PubMedCrossRef

DeWitt, DL, Smith, WL 1988Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequenceProc Natl Acad Sci USA8514121416PubMedCrossRef

10.

Kujubu, DA, Fletcher, BS, Varnum, BC, Lim, RW, Herschman, HR 1991TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologueJ Biol Chem2661286612872PubMed

11.

Xie, WL, Chipman, JG, Robertson, DL, Erikson, RL, Simmons, DL 1991Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicingProc Natl Acad Sci USA8826922696PubMedCrossRef

12.

Oshima, M, Dinchuk, JE, Kargman, SL, et al. 1996Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)Cell87803809PubMedCrossRef

13.

Taketo, MM 1998Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)J Natl Cancer Inst9016091620PubMedCrossRef

14.

Kawamori, T, Rao, CV, Seibert, K, Reddy, BS 1998Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesisCancer Res58409412PubMed

15.

Kishimoto, Y, Takata, N, Jinnai, T, et al. 2000Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethaneGut47812819PubMedCrossRef

16.

Steinbach, G, Lynch, PM, Phillips, RK, et al. 2000The effect ofcelecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposisN Engl J Med34219461952PubMedCrossRef

17.

Rahme, E, Barkun, AN, Toubouti, Y, Bardou, M 2003The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrenceGastroenterology125404412PubMedCrossRef

18.

Tsujii, M, Kawano, S, DuBois, RN 1997Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potentialProc Natl Acad Sci USA9433363340PubMedCrossRef

19.

Nagatsuka, I, Yamada, N, Shimizu, S, et al. 2002Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancerInt J Cancer100515519PubMedCrossRef

20.

Yao, M, Kargman, S, Lam, EC, et al. 2003Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in miceCancer Res63586592PubMed

21.

Matrisian, LM 1992The matrix-degrading metalloproteinasesBioessays14455463PubMedCrossRef

22.

Stetler-Stevenson, WG 2001The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesisSurg Oncol Clin N Am10383392PubMed

23.

Nelson, AR, Fingleton, B, Rothenberg, ML, Matrisian, LM 2000Matrix metalloproteinases: biologic activity and clinical implicationsJ Clin Oncol1811351149PubMed

24.

Sato, H, Takino, T, Okada, Y, et al. 1994A matrix metalloproteinase expressed on the surface of invasive tumour cellsNature3706165PubMedCrossRef

25.

Okada, A, Bellocq, JP, Rouyer, N, et al. 1995Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomasProc Natl Acad Sci USA9227302734PubMedCrossRef

26.

Nabeshima, K, Inoue, T, Shimao, Y, et al. 2000Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factorCancer Res6033643369PubMed

27.

Sano, H, Kawahito, Y, Wilder, RL, et al. 1995Expression of cyclooxygenase-1 and -2 in human colorectal cancerCancer Res5537853789PubMed

28.

Sheehan, KM, Sheahan, K, O'Donoghue, DP, et al. 1999The relationship between cyclooxygenase-2 expression and colorectal cancerJAMA28212541257PubMedCrossRef

29.

Masunaga, R, Kohno, H, Dhar, DK, et al. 2000Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patientsClin Cancer Res640644068PubMed

30.

Tomozawa, S, Tsuno, NH, Sunami, E, et al. 2000Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancerBr J Cancer83324328PubMedCrossRef

31.

Joo, YE, Kim, HS, Min, SW, et al. 2002Expression of cyclooxygenase-2 protein in colorectal carcinomasInt J Gastrointest Cancer31147154PubMedCrossRef

32.

Yamauchi, T, Watanabe, M, Kubota, T, et al. 2002Cyclooxygenase-2 expression as a new marker for patients with colorectal cancerDis Colon Rectum4598103PubMedCrossRef

33.

Zhang, H, Sun, XF 2002Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancerAm J Gastroenterol9710371041PubMedCrossRef

34.

Petersen, S, Haroske, G, Hellmich, G, Ludwig, K, Petersen, C, Eicheler, W 2002COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcomeAnticancer Res2212251230PubMed

35.

Buecher, B, Heymann, MF, Lievre, A, et al. 2003Cyclo-oxygenase-2 over-expression in sporadic colorectal carcinoma without lymph node involvementAliment Pharmacol Ther18731740PubMedCrossRef

36.

Wu, AW, Gu, J, Ji, JF, Li, ZF, Xu, GW 2003Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosisWorld J Gastroenterol919901994PubMed

37.

Knosel, T, Yu, Y, Stein, U, et al. 2004Overexpression of cyclooxygenase-2 correlates with chromosomal gain at the cyclooxygenase-2 locus and decreased patient survival in advanced colorectal carcinomasDis Colon Rectum477077PubMedCrossRef

38.

Liang, JT, Huang, KC, Jeng, YM, Lee, PH, Lai, HS, Hsu, HC 2004Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancerBr J Surg91355361PubMedCrossRef

39.

Xiong, B, Sun, TJ, Hu, WD, Cheng, FL, Mao, M, Zhou, YF 2005Expression of cyclooxygenase-2 in colorectal cancer and its clinical significanceWorld J Gastroenterol1111051108PubMed

40.

Soumaoro, LT, Uetake, H, Higuchi, T, Takagi, Y, Enomoto, M, Sugihara, K 2004Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancerClin Cancer Res1084658471PubMedCrossRef

41.

Tatsuguchi, A, Matsui, K, Shinji, Y, et al. 2004Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissueHum Pathol35488495PubMedCrossRef

42.

Hida, T, Yatabe, Y, Achiwa, H, et al. 1998Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomasCancer Res5837613764PubMed

43.

Karnes, WE,Jr, Shattuck-Brandt, R, Burgart, LJ, et al. 1998Reduced COX-2 protein in colorectal cancer with defective mismatch repairCancer Res5854735477PubMed

44.

Kikuchi, R, Noguchi, T, Takeno, S, Kubo, N, Uchida, Y 2000Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinomaBr J Cancer83215218PubMedCrossRef

45.

Hiraoka, N, Allen, E, Apel, IJ, Gyetko, MR, Weiss, SJ 1998Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysinsCell95365377PubMedCrossRef

46.

Hotary, KB, Allen, ED, Brooks, PC, Datta, NS, Long, MW, Weiss, SJ 2003Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrixCell1143345PubMedCrossRef

47.

Takahashi, M, Tsunoda, T, Seiki, M, Nakamura, Y, Furukawa, Y 2002Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancersOncogene2158615867PubMedCrossRef

48.

Murai, S, Umemiya, T, Seiki, M, Harigaya, K 2004Expression and localization of membrane-type-1 matrix metalloproteinase, CD 44, and laminin-5gamma2 chain during colorectal carcinoma tumor progressionVirchows Arch445271278PubMedCrossRef

49.

Howe, LR, Subbaramaiah, K, Chung, WJ, Dannenberg, AJ, Brown, AM 1999Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cellsCancer Res5915721577PubMed

50.

Araki, Y, Okamura, S, Hussain, SP, et al. 2003Regulation of cyclooxygenase-2 expression by the Wnt and ras pathwaysCancer Res63728734PubMed

51.

Tsujii, M, DuBois, RN 1995Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2Cell83493501PubMedCrossRef

52.

Tsujii, M, Kawano, S, Tsuji, S, Sawaoka, H, Hori, M, DuBois, RN 1998Cyclooxygenase regulates angiogenesis induced by colon cancer cellsCell93705716PubMedCrossRef

53.

Mukai, M, Sadahiro, S, Tokunaga, N, et al. 1999The expression of MMP-2 and TIMP-2 in patients with primary colorectal adenocarcinoma: correlation with liver metastasisOncol Rep6969973PubMed

54.

Curran, S, Dundas, SR, Buxton, J, Leeman, MF, Ramsay, R, Murray, GI 2004Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancersClin Cancer Res1082298234PubMedCrossRef

Title: Cyclooxygenase-2 Expression Correlates With Membrane-Type-1 Matrix Metalloproteinase Expression in Colorectal Cancer Tissue
Authors: Hongfei Guo, M.D.
Atsushi Tatsuguchi, M.D.
Seiichi Shinji, M.D.
Shunji Fujimori, M.D.
Shu Tanaka, M.D.
Katya Gudis, M.S.
Yuichi Sugisaki, M.D.
Kiyonori Furukawa, M.D.
Takashi Tajiri, M.D.
Yuh Fukuda, M.D.
Teruyuki Kishida, M.D.
Choitsu Sakamoto, M.D.
Publication date: 01-08-2006
Publisher: Springer-Verlag
Published in: Diseases of the Colon & Rectum / Issue 8/2006
Print ISSN: 0012-3706
Electronic ISSN: 1530-0358
DOI: https://doi.org/10.1007/s10350-006-0588-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cyclooxygenase-2 Expression Correlates With Membrane-Type-1 Matrix Metalloproteinase Expression in Colorectal Cancer Tissue

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2006

Electrical Stimulation and Pelvic Floor Muscle Training With Biofeedback in Patients With Fecal Incontinence: A Cohort Study of 281 Patients

How Does an Historic Control Study of a Surgical Procedure Compare With the “Gold Standard”?

Impact of Blood Transfusions on Recurrence and Survival After Rectal Cancer Surgery

The Authors Reply

The Authors Reply

Intangible Costs and Benefits of Ulcerative Colitis Surveillance: A Patient Survey